Viking Therapeutics, Inc
Symbol: VKTX (NASDAQ)
26.07
▼ (-0.80%) -0.210
Company Description:
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Key Stats
- Today's Open: $26.145
- Today's High: $26.335
- Today's Low: $25.89
- Today's Volume: 19.44K
- Yesterday Close: $26.28
- Yesterday High: $26.55
- Yesterday Low: $25.04
- Yesterday Volume: 5.01M
- Last Min Volume: 383
- Last Min High: $26.07
- Last Min Low: $26.07
- Last Min VWAP: $26.07
Company Profile
- Name: Viking Therapeutics, Inc
- Website: https://www.vikingtherapeutics.com
- Listed Date: 2015-04-29
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001607678
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $2.96B
- Round Lot: 100
- Outstanding Shares: 112.44M
- Asset Type: CS
RECENT FILINGS FOR VKTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-19 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-07-23 | 10-Q | View |
| 2025-07-23 | 8-K | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 144 | View |
| 2025-07-03 | 144 | View |
| 2025-07-03 | 144 | View |
| 2025-05-27 | 8-K | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
| 2025-04-24 | 10-Q | View |
| 2025-04-23 | DEFA14A | View |
| 2025-04-23 | DEFR14A | View |
| 2025-04-23 | 8-K | View |
| 2025-04-23 | 8-K | View |
| 2025-04-23 | SCHEDULE 13G/A | View |
| 2025-04-21 | UPLOAD | View |
| 2025-04-14 | 4 | View |
Latest News on VKTX